Clinical outcomes in the percutaneous coronary intervention of in-stent restenosis with everolimus-eluting stents

Journal of Invasive Cardiology

Volumn 26, Issue 9, 2014, Pages 420-426

  Lee, Michael S ^a   Yang, Tae ^a   Mahmud, Ehtisham ^b   Park, Kyung Woo ^c   Kim, Hyo Soo ^c   Kim, Moo Hyun ^d   Dangas, George ^e   Hermiller, James ^f   Krucoff, Mitchell ^g   Rutledge, David ^h  

^a UCLA MEDICAL CENTER   (United States)

^b UCSD MEDICAL CENTER   (United States)

^c Seoul National University College of Medicine   (South Korea)

^d Dong A University   (South Korea)

^e MOUNT SINAI HOSPITAL   (United States)

^f St Vincent s Heart Center of Indiana   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h ABBOTT VASCULAR   (United States)

Author keywords

drug eluting stents; in stent restenosis; restenosis

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FAMILY HISTORY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IN-STENT RESTENOSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; SMOKING; STENT THROMBOSIS; UNSTABLE ANGINA PECTORIS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; CLINICAL TRIAL; COMPLICATION; CORONARY RESTENOSIS; CORONARY STENOSIS; INCIDENCE; LONGITUDINAL STUDY; MIDDLE AGED; MYOCARDIAL INFARCTION; REGISTER; RISK FACTOR; TIME; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84907046662     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Moses JW, Leon MB, Popma JJ, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323.
2. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897-1907.
3. Park SJ, Kim KH, Oh IY, et al. Comparison of plain balloon and cutting balloon angioplasty for the treatment of restenosis with drug-eluting stents vs bare metal stents. Circ J. 2010;74(9):1837-1845.
4. Ko YG, Kim JS, Kim BK, et al; KISS Investigators. Efficacy of drug-eluting stents for treating in-stent restenosis of drug-eluting stents (from the Korean DES ISR multicenter registry study [KISS]). Am J Cardiol. 2012;109(5):607-613.
5. Chevalier B, Moulichon R, Teiger E, et al. One-Year Results of the CRISTAL trial, a randomized comparison of Cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents. J Interv Cardiol. 2012;25(6):586-595. 2012 Sep 20 (Epub ahead of print).
6. Alfonso F, Perez-Vizcayno MJ, Hernandez R, et al; RIBS-II Investigators. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol. 2006;47(11):2152-2160.
7. Torguson R, Sabate M, Deible R, et al. Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. Am J Cardiol. 2006;98(10):1340-1344 (Epub 2006 Sep 26).
8. Bonello L, Kaneshige K, De Labriolle A, et al. Vascular brachytherapy for patients with drug-eluting stent restenosis. J Interv Cardiol. 2008;21(6):528-534 (Epub 2008 Oct 29).
9. Holmes Jr. D.R., Teirstein P, Satler L, et al; SISR Investigators. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA. 2006;295(11):1264-1273 (Epub 2006 Mar 12).
10. Stone GW, Ellis SG, OShaughnessy CD, et al; TAXUS V ISR Investigators. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA. 2006;295(11):1253-1263 (Epub 2006 Mar 12).
11. Almalla M, Pross V, Marx N, Hoffmann R. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis. Coron Artery Dis. 2012;23(7):492-496.
12. Almalla M, Schrder JW, Pross V, Stegemann E, Marx N, Hoffmann R. Everolimus-eluting versus paclitaxel-eluting stents for treatment of bare metal stent restenosis. Am J Cardiol. 2011;108(4):518-522 (Epub 2011 May 31).
13. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117,762 patient-years of follow-up from randomized trials. Circulation. 2012;125(23):2873-2891 (Epub 2012 May 14).
14. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344-2351.
15. Krucoff MW, Rutledge DR, Gruberg L, et al. A new era of prospective real-world safety evaluation primary report of Xience V USA (Xience V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). JACC Cardiovasc Interv. 2011;4(12):1298-1309.
16. Le Feuvre C, Healy-Brucker A, Helft G, et al. Long-term follow-up of patients with sirolimus-eluting stents for treatment of bare-metal in-stent restenosis. Int J Cardiol. 2010;140(2):219-225 (Epub 2008 Dec 2).
17. Lee MS, Yang T, Lasala JM, et al. Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme. EuroIntervention. 2011;7(3):314-322.
18. Naidu SS, Krucoff MW, Rutledge DR, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after Xience V implantation: results from the 8,061-patient Xience V United States study. JACC Cardiovasc Interv. 2012;5(6):626-635.
19. Sarno G, Lagerqvist B, Frbert O, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of new-generation drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33(5):606-613 (Epub 2012 Jan 9).
20. Applegate RJ, Yaqub M, Hermiller JB, et al. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III trial). Am J Cardiol. 2011;107(6):833-840 (Epub 2011 Jan 19).
21. Leon MB, Nikolsky E, Cutlip DE, et al; ENDEAVOR IV Investigators. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv. 2010;3(10):1043-1050.
22. de Waha A, Dibra A, Byrne RA, et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2011;4(4):371-377 (Epub 2011 Jul 26).
23. Yan RQ, Gao LJ, Chen JL. Everolimus versus sirolimus-eluting stents for the treatment of sirolimus-eluting stent restenosis. Int J Cardiol. 2013;165(3):568-569 (Epub 2012 Oct 2).
24. Mehilli J, Byrne RA, Tiroch K, et al; ISAR-DESIRE 2 Investigators. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol. 2010;55(24):2710-2716 (Epub 2010 Mar 11).